Name | bpV(HOpic) (potassium salt) |
---|---|
Synonyms | MFCD01862576 |
Description | BpV(HOpic) is a potent and selective inhibitor of PTEN with an IC50 of 14 nM. Nanocarrier-BpV(HOpic) has neuroprotective activity[1][2]. |
---|---|
Related Catalog | |
Target |
IC50: 14 nM (PTEN)[1] |
In Vitro | BpV(HOpic) (1 µM) treatment increases cell proliferation and decreases apoptotic rate in MG63 cells received Cisplatin treatment[3]. Bpv(HOpic) (1 µM) enhances migration of C2C12 myoblasts and is associated with activation of PI3K/AKT and MAPK/ERK signalling pathways[4]. BpV(HOpic) (1 µM; 48 hours) promotes the initiation of swine follicle growth and development, similar as in rodent species and humans[5]. Nanocarrier-BpV(HOpic) enhances axonal outgrowth of neurons[2]. |
In Vivo | BpV(HOpic) (0.05 mg/kg; i.p.) at reperfusion ameliorates liver ischemia/reperfusion (I/R) injury in vivo[6]. BpV(HOpic) (200 μg/kg; i.p.) exacerbates renal dysfunction and promotes tubular damage in mice with ischemia/reperfusion injury (IRI)[7]. Animal Model: Male Wistar rats are subjected to partial hepatic ischemia[6] Dosage: 0.05 mg/kg Administration: I.p. injections at the start of reperfusion Result: Ameliorated reoxygenation injury and reproduced the hepatoprotective effects obtained by adenosine A2A receptor stimulation. Animal Model: Male C57BL/6 mice (8-12 weeks old; 20-30 g ) are subjected to renal ischemia[7] Dosage: 200 μg/kg Administration: I.p. injections 1 h before ischemia and then administers every 6 h after ischemia for 24 hr Result: Raised the level of serum creatinine and blood serum urea nitrogen. |
References |
Molecular Formula | C6H4K2NO8V |
---|---|
Molecular Weight | 347.23600 |
Exact Mass | 346.86500 |
PSA | 155.58000 |
Storage condition | -20℃ |
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H315-H319 |
Precautionary Statements | P305 + P351 + P338 |
RIDADR | NONH for all modes of transport |